{"description":"Documents published on 08/12/2026","count":70,"total_pages":4,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bpublication_date%5D%5Bis%5D=2026-08-12&format=json&page=2&search_after_cursor=WzE3ODY0OTI4MDAwMDAsIjIwMjYtMTY0MzIiXQ","results":[{"title":"Appellate Jurisdiction Update II","type":"Rule","abstract":"The Merit Systems Protection Board (MSPB or Board) is amending its regulations to remove references to MSPB's jurisdiction over probationary termination, suitability, and reduction-in-force (RIF) appeals. This revision reflects the Office of Personnel Management's (OPM's) rescission of the MSPB's jurisdiction to hear these types of appeals. The rule retains MSPB's statutory jurisdiction over Foreign Service reduction-in-force appeals under 22 U.S.C. 4010a.","document_number":"2026-16456","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16456/appellate-jurisdiction-update-ii","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16456.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16456.pdf?1786452320","publication_date":"2026-08-12","agencies":[{"raw_name":"MERIT SYSTEMS PROTECTION BOARD","name":"Merit Systems Protection Board","id":285,"url":"https://www.federalregister.gov/agencies/merit-systems-protection-board","json_url":"https://www.federalregister.gov/api/v1/agencies/285","parent_id":null,"slug":"merit-systems-protection-board"}],"excerpts":"The Merit Systems Protection Board (MSPB or Board) is amending its regulations to remove references to MSPB's jurisdiction over probationary termination, suitability, and reduction-in-force (RIF) appeals. This revision reflects the Office of Personnel..."},{"title":"Community Reinvestment Act Regulations","type":"Proposed Rule","abstract":"The Office of the Comptroller of the Currency (OCC) and the Federal Deposit Insurance Corporation (FDIC) are proposing to amend their Community Reinvestment Act rules by making certain substantive, technical, and process-oriented changes to refocus on the statutory objective of encouraging banks to meet the credit needs of their communities; to better ensure that community development grants reach the communities they are intended to benefit; to reduce unnecessary burden, particularly for community banks; and to provide greater clarity for how to obtain CRA consideration. The OCC and the FDIC are also proposing certain technical changes to their rules implementing the Community Reinvestment Act sunshine requirements of the Federal Deposit Insurance Act. In addition, the OCC is proposing similar technical changes to its Public Welfare Investments rule and its Rules, Policies, and Procedures for Corporate Activities.","document_number":"2026-16454","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16454/community-reinvestment-act-regulations","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16454.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16454.pdf?1786452319","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF THE TREASURY","name":"Treasury Department","id":497,"url":"https://www.federalregister.gov/agencies/treasury-department","json_url":"https://www.federalregister.gov/api/v1/agencies/497","parent_id":null,"slug":"treasury-department"},{"raw_name":"Office of the Comptroller of the Currency","name":"Comptroller of the Currency","id":80,"url":"https://www.federalregister.gov/agencies/comptroller-of-the-currency","json_url":"https://www.federalregister.gov/api/v1/agencies/80","parent_id":497,"slug":"comptroller-of-the-currency"},{"raw_name":"FEDERAL DEPOSIT INSURANCE CORPORATION","name":"Federal Deposit Insurance Corporation","id":164,"url":"https://www.federalregister.gov/agencies/federal-deposit-insurance-corporation","json_url":"https://www.federalregister.gov/api/v1/agencies/164","parent_id":null,"slug":"federal-deposit-insurance-corporation"}],"excerpts":"The Office of the Comptroller of the Currency (OCC) and the Federal Deposit Insurance Corporation (FDIC) are proposing to amend their Community Reinvestment Act rules by making certain substantive, technical, and process-oriented changes to refocus on..."},{"title":"Government Owned Invention Available for License: MC38 B2m KO Cell Line","type":"Notice","abstract":"The National Cancer Institute (NCI) seeks licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line that models tumor resistance to PD-1/PD-L1 checkpoint blockade caused by loss of MHC-I antigen presentation. This research tool provides an opportunity to study checkpoint-refractory tumors and evaluate alternative or combination immunotherapy strategies for cancers that evade conventional T-cell-mediated recognition.","document_number":"2026-16449","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16449/government-owned-invention-available-for-license-mc38-b2m-ko-cell-line","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16449.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16449.pdf?1786452319","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"The National Cancer Institute (NCI) seeks licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line that models tumor resistance to PD-1/PD-L1 checkpoint blockade caused by loss of MHC-I antigen presentation. This research..."},{"title":"UChicago Argonne LLC et al; Notice of Decision on Application for Duty-Free Entry of Scientific Instruments","type":"Notice","abstract":null,"document_number":"2026-16448","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16448/uchicago-argonne-llc-et-al-notice-of-decision-on-application-for-duty-free-entry-of-scientific","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16448.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16448.pdf?1786452319","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"International Trade Administration","name":"International Trade Administration","id":261,"url":"https://www.federalregister.gov/agencies/international-trade-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/261","parent_id":54,"slug":"international-trade-administration"}],"excerpts":null},{"title":"Pacific Northwest National Laboratory et al; Application(s) for Duty-Free Entry of Scientific Instruments","type":"Notice","abstract":null,"document_number":"2026-16447","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16447/pacific-northwest-national-laboratory-et-al-applications-for-duty-free-entry-of-scientific","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16447.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16447.pdf?1786452319","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"International Trade Administration","name":"International Trade Administration","id":261,"url":"https://www.federalregister.gov/agencies/international-trade-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/261","parent_id":54,"slug":"international-trade-administration"}],"excerpts":null},{"title":"Wooden Bedroom Furniture From the People's Republic of China: Final Results of Antidumping Duty Administrative Review; 2024","type":"Notice","abstract":"The U.S. Department of Commerce (Commerce) continues to determine that 11 companies under review did not establish their entitlement to a separate rate and are thus part of the People's Republic of China (China)-wide entity and subject to the China-wide entity rate. The period review (POR) is January 1, 2024, through December 31, 2024.","document_number":"2026-16446","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16446/wooden-bedroom-furniture-from-the-peoples-republic-of-china-final-results-of-antidumping-duty","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16446.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16446.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"International Trade Administration","name":"International Trade Administration","id":261,"url":"https://www.federalregister.gov/agencies/international-trade-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/261","parent_id":54,"slug":"international-trade-administration"}],"excerpts":"The U.S. Department of Commerce (Commerce) continues to determine that 11 companies under review did not establish their entitlement to a separate rate and are thus part of the People's Republic of China (China)-wide entity and subject to the..."},{"title":"Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Steel Import License","type":"Notice","abstract":null,"document_number":"2026-16445","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16445/agency-information-collection-activities-submission-to-the-office-of-management-and-budget-omb-for","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16445.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16445.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"International Trade Administration","name":"International Trade Administration","id":261,"url":"https://www.federalregister.gov/agencies/international-trade-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/261","parent_id":54,"slug":"international-trade-administration"}],"excerpts":null},{"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of BL-760 Dye for Intraoperative Fluorescence Imaging","type":"Notice","abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to OptoSurgical LLC (\"OptoSurgical\"), a company located in Columbia, Maryland, the United States of America.","document_number":"2026-16444","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16444/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-bl-760-dye-for","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16444.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16444.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent..."},{"title":"Government Owned Invention Available for License: Monoclonal Antibody (RO4) That Reacts With the Juxta-Membrane Region of Mesothelin","type":"Notice","abstract":"The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.","document_number":"2026-16443","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16443/government-owned-invention-available-for-license-monoclonal-antibody-ro4-that-reacts-with-the","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16443.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16443.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers."},{"title":"Government Owned Invention Available for License: Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer","type":"Notice","abstract":"The National Cancer Institute (NCI) seeks research co- development partners and/or licensees to develop a collection of anti- CE1 antibodies for liver cancer treatment.","document_number":"2026-16442","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16442/government-owned-invention-available-for-license-human-antibodies-targeting-beneficial-viral-peptide","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16442.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16442.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"The National Cancer Institute (NCI) seeks research co- development partners and/or licensees to develop a collection of anti- CE1 antibodies for liver cancer treatment."},{"title":"Government Owned Invention Available for License: DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification","type":"Notice","abstract":"This technology encompasses a DNA methylation-based diagnostic platform designed to improve the accuracy and consistency of cancer classification, with demonstrated utility for tumors of the central nervous system, kidney, and hematopoietic system. By identifying disease-specific methylation signatures, the approach reduces interobserver variability and enhances diagnostic confidence. The central nervous system (CNS) classifier is built from a curated reference set of 16,567 methylation profiles and organizes tumors into 22 families and 133 clinically relevant diagnostic classes, including 21 newly developed methylation classes not represented in other existing tools. Across multiple independent validation cohorts (n = 5,875), the classifier demonstrated robust performance, and in a clinical-impact analysis of 1,204 NIH validation cases, methylation profiling materially influenced final diagnosis in 74.4% of cases by refining, increasing precision, or reclassifying. The CNS classifier was deployed as a user-facing software tool, MethylScape Analysis, which streamlines methylation-based classification workflows for CNS tumors, https://methylscape.ccr.cancer.gov/. The development of multiple specialized classifiers supports a more granular understanding of tumor biology and informed clinical decision-making.","document_number":"2026-16441","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16441/government-owned-invention-available-for-license-dna-methylation-based-cancer-diagnostics-for","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16441.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16441.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"This technology encompasses a DNA methylation-based diagnostic platform designed to improve the accuracy and consistency of cancer classification, with demonstrated utility for tumors of the central nervous system, kidney, and hematopoietic system. By..."},{"title":"NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions","type":"Notice","abstract":"Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.","document_number":"2026-16440","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16440/nih-owned-invention-available-for-license-soluble-tissue-factor-a-novel-target-and-antibodies-for","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16440.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16440.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing..."},{"title":"Government Owned Invention Available for License: Quantitative Particle Identification (QPID) Digital Autoradiography System","type":"Notice","abstract":"The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a QPID digital autoradiography system with particle identification capabilities.","document_number":"2026-16439","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16439/government-owned-invention-available-for-license-quantitative-particle-identification-qpid-digital","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16439.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16439.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a QPID digital autoradiography system with particle identification capabilities."},{"title":"NIH Owned Invention Available for License: Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy","type":"Notice","abstract":"Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL- 12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.","document_number":"2026-16438","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16438/nih-owned-invention-available-for-license-drug-regulatable-inducible-expression-of-membrane-bound","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16438.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16438.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL- 12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR,..."},{"title":"Agency Information Collection Activities; Proposed eCollection eComments Requested; New Information Collection; USAO-PR COMMUNITY OUTREACH REQUEST FORM Feedback Form Package","type":"Notice","abstract":"The USAO-PR, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.","document_number":"2026-16437","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16437/agency-information-collection-activities-proposed-ecollection-ecomments-requested-new-information","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16437.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16437.pdf?1786452317","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"}],"excerpts":"The USAO-PR, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995."},{"title":"Dauphin Island Gathering Partners; Notice of Application and Establishing Intervention Deadline","type":"Notice","abstract":null,"document_number":"2026-16436","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16436/dauphin-island-gathering-partners-notice-of-application-and-establishing-intervention-deadline","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16436.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16436.pdf?1786452317","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF ENERGY","name":"Energy Department","id":136,"url":"https://www.federalregister.gov/agencies/energy-department","json_url":"https://www.federalregister.gov/api/v1/agencies/136","parent_id":null,"slug":"energy-department"},{"raw_name":"Federal Energy Regulatory Commission","name":"Federal Energy Regulatory Commission","id":167,"url":"https://www.federalregister.gov/agencies/federal-energy-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/167","parent_id":136,"slug":"federal-energy-regulatory-commission"}],"excerpts":null},{"title":"Mountain Valley Pipeline, LLC; Notice of Availability of the Environmental Assessment for the Proposed Mountain Valley Pipeline Boost Project","type":"Notice","abstract":null,"document_number":"2026-16435","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16435/mountain-valley-pipeline-llc-notice-of-availability-of-the-environmental-assessment-for-the-proposed","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16435.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16435.pdf?1786452317","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF ENERGY","name":"Energy Department","id":136,"url":"https://www.federalregister.gov/agencies/energy-department","json_url":"https://www.federalregister.gov/api/v1/agencies/136","parent_id":null,"slug":"energy-department"},{"raw_name":"Federal Energy Regulatory Commission","name":"Federal Energy Regulatory Commission","id":167,"url":"https://www.federalregister.gov/agencies/federal-energy-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/167","parent_id":136,"slug":"federal-energy-regulatory-commission"}],"excerpts":null},{"title":"Issuance of Multiple Exemptions","type":"Notice","abstract":"The U.S. Nuclear Regulatory Commission (NRC) is issuing a single notice to announce the issuance of four exemptions in response to requests as detailed in the available documents.","document_number":"2026-16434","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16434/issuance-of-multiple-exemptions","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16434.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16434.pdf?1786452317","publication_date":"2026-08-12","agencies":[{"raw_name":"NUCLEAR REGULATORY COMMISSION","name":"Nuclear Regulatory Commission","id":383,"url":"https://www.federalregister.gov/agencies/nuclear-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/383","parent_id":null,"slug":"nuclear-regulatory-commission"}],"excerpts":"The U.S. Nuclear Regulatory Commission (NRC) is issuing a single notice to announce the issuance of four exemptions in response to requests as detailed in the available documents."},{"title":"Information Collection: Physical Protection of Category 1 and 2 Quantities of Radioactive Material","type":"Notice","abstract":"The U.S. Nuclear Regulatory Commission (NRC) invites public comment on the renewal of Office of Management and Budget (OMB) approval for an existing collection of information. The information collection is entitled, \"Physical Protection of Category 1 and 2 Quantities of Radioactive Material.\"","document_number":"2026-16433","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16433/information-collection-physical-protection-of-category-1-and-2-quantities-of-radioactive-material","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16433.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16433.pdf?1786452317","publication_date":"2026-08-12","agencies":[{"raw_name":"NUCLEAR REGULATORY COMMISSION","name":"Nuclear Regulatory Commission","id":383,"url":"https://www.federalregister.gov/agencies/nuclear-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/383","parent_id":null,"slug":"nuclear-regulatory-commission"}],"excerpts":"The U.S. Nuclear Regulatory Commission (NRC) invites public comment on the renewal of Office of Management and Budget (OMB) approval for an existing collection of information. The information collection is entitled, \"Physical Protection of Category 1..."},{"title":"Imposition of Import Restrictions on Categories of Archaeological and Ethnological Material of Nepal","type":"Rule","abstract":"This document amends U.S. Customs and Border Protection (CBP) regulations to reflect the imposition of import restrictions on certain archaeological and ethnological material from the Federal Democratic Republic of Nepal (Nepal). These restrictions are imposed pursuant to an agreement between the United States and Nepal, entered into under the authority of the Convention on Cultural Property Implementation Act. This document amends the CBP regulations by adding Nepal to the list of countries which have bilateral agreements with the United States imposing cultural property import restrictions and contains the Designated List, describing the archaeological and ethnological material to which the restrictions apply.","document_number":"2026-16432","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16432/imposition-of-import-restrictions-on-categories-of-archaeological-and-ethnological-material-of-nepal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16432.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16432.pdf?1786452317","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HOMELAND SECURITY","name":"Homeland Security Department","id":227,"url":"https://www.federalregister.gov/agencies/homeland-security-department","json_url":"https://www.federalregister.gov/api/v1/agencies/227","parent_id":null,"slug":"homeland-security-department"},{"raw_name":"U.S. Customs and Border Protection","name":"U.S. Customs and Border Protection","id":501,"url":"https://www.federalregister.gov/agencies/u-s-customs-and-border-protection","json_url":"https://www.federalregister.gov/api/v1/agencies/501","parent_id":227,"slug":"u-s-customs-and-border-protection"}],"excerpts":"This document amends U.S. Customs and Border Protection (CBP) regulations to reflect the imposition of import restrictions on certain archaeological and ethnological material from the Federal Democratic Republic of Nepal (Nepal). These restrictions are..."}]}